Law360, New York (July 23, 2007, 12:00 AM ET) -- On the heels of several suits Sanofi-Aventis U.S. LLC has launched against generics over the blockbuster cancer drug Eloxatin, Mayne Pharma Ltd. filed a suit for judgment of noninfringement of Sanofi's patents.
The suit, filed Wednesday in the eastern Virginia district court, contends that one of the patents that cover Sanofi's oxiplatin formulations and manufacturing processes—6,306,902—is invalid and unenforceable and therefore is not infringed by any of Mayne's actions. It seeks declaratory judgment saying as much.
According to the complaint, the '902 patent is the U.S....
Mayne Renews Crusade For Colon Cancer Drug
To view the full article, take a free trial now.
